Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24951966 | 0.88 | ADAM17 (0.42) | ADAM17 | |
| SCHEMBL24018572 | 0.83 | ADAM17 (0.46) | ADAM17 | |
| SCHEMBL20621770 | 0.80 | ADAM17 (0.43) | ADAM17 | |
| SCHEMBL24018625 | 0.75 | ADAM17 (0.44) | ADAM17 | |
| SCHEMBL24952371 | 0.74 | ADAM17 (0.51) | ADAM17L3MBTL1 | |
| SCHEMBL20621728 | 0.72 | ADAM17 (0.42) | ADAM17 | |
| SCHEMBL24018590 | 0.69 | ADAM17 (0.44) | ADAM17 | |
| SCHEMBL24018510 | 0.69 | ADAM17 (0.55) | ADAM17 | |
| SCHEMBL20621736 | 0.66 | ADAM17 (0.51) | ADAM17 | |
| SCHEMBL20622025 | 0.66 | ADAM17 (0.42) | ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | ABCB11, SLC10A1, SLC5A1 | ADAM17 1186/4885L3MBTL1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.